BRD4 and pancreatic ductal adenocarcinoma: Combination therapy with the BRD4 inhibitor JQ1 and the CDK7 inhibitor THZ1 synergistically reduces super-enhancer-associated oncogene expression and exerts synergistical anticancer effects against pancreatic ductal adenocarcinoma and head and neck squamous cell carcinoma in vitro and in mouse models [42, 43].